Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › luspatercept

luspatercept

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of luspatercept

9 trials tracked of luspatercept: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 543 citations.

9Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 7
  1. Phase 3 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Completed · 543 cited
  2. Phase 3 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia Completed · 116 cited
  3. Phase 2 Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) Completed
  4. Phase 2 Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) Completed
  5. Phase 2 A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia Completed
  6. Phase 2 A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence Completed
Show 3 more trials
  1. Phase 2 Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) Completed
  2. Phase 2 An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion Completed
  3. Phase 2 Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS
Oncology Meta-analysis
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS Different Medications Show Different Benefits for Myelodysplastic Syndromes
This systematic review and network meta-analysis of 20 trials involving 2,877 participants evaluated pharmacological treatments for lower-ri…
New research shows different medications offer varying benefits for patients with lower-risk myelodysplastic syndromes based on specific hea…
Frontiers Jun 17, 2026